Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  bicalutamide
Find trials that include:  Any drugs shown
Results 1-13 of 13 for your search:
Start Over
Radiation Therapy with or without Androgen-Deprivation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0815, NCI-2011-01948, CDR0000648194, NCT00936390
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR106935, NCI-2016-00117, 56021927PCR3003, NCT02531516
Radiation Therapy, Hormone Therapy, and Docetaxel in Treating Patients with High-Risk Prostate Cancer Previously Treated with Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 85
Trial IDs: 12313, NCI-2011-01380, 4P-06-3, CR00001450, HS-08-00201, NCT00669162
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
High-Dose Brachytherapy in Treating Patients with Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: PROS0065, NCI-2015-00089, 350, NCT02346253
Palbociclib and Bicalutamide in Treating Patients with Metastatic Androgen Receptor Positive or Triple Negative Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-207, NCI-2015-02043, NCT02605486
LHRH Analogue Therapy with Enzalutamide or Bicalutamide in Treating Patients with Metastatic Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-083, NCI-2014-00212, 1311012529, NCT02058706
Androgen Deprivation Therapy with or without Palbociclib Isethionate in Treating Patients with RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.117, NCI-2014-01922, HUM00082715, NCT02059213
Hormone Therapy and Radiation Therapy in Treating Patients with Non-metastatic, Intermediate, or High Risk Prostate Cancer
Phase: No phase specified
Type: Treatment
Age: 70 and over
Trial IDs: 10-625-A, NCI-2015-01652, NCI-2015-01608, NCT01342367
Intensity Modulated Radiation Therapy with Stereotactic Radiosurgery Boost and Hormone Therapy in Treating Patients with Prostate Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CCRO025, NCI-2014-01486, 421870, NCT02064036
Bicalutamide with or without Metformin Hydrochloride in Lowering PSA Levels in Overweight or Obese Patients with Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GU-079, NCI-2015-02227, 15-1015, NCT02614859
Start Over